Mara Goldstein describes what she is watching for at the conference and discusses Iovance, Xencor, Syndax, Autolus, and more.

Dr. Shawver describes how Capstan plans to achieve in-vivo CAR-T by utilizing LNPs to deliver mRNA to lymphocytes in the body.

Dan O'Connor and Shawn Zhang describe Ambrx's HER2 and PSMA targeting antibody-drug conjugate programs.

Troy Wilson describes the science behind Kura's menin inhibitor and farnesyl transferase inhibitor programs.

Dr. Topol discusses the latest in COVID, GLP-1s, NASH, CRISPR, and AI in medicine.

Sarah Boyce explains the rationale for using AOCs against muscle disorders like Myotonic dystrophy type 1 and DMD.

Kristin Yarema, CEO starting Jan 1st, describes Poseida's approach to allo CAR-T and then CMC expert Chad Headlee gives us a tour.

Kelly Cloud describes the assets, infrastructure, and incentives that the Dallas area offers life sciences companies.

BioNTX CEO Kathleen Otto gives us a summary of the biotech activity in North Texas.

Alex Thompson gives a deep dive into the I&I space and discusses Apogee, Aeglea, argenx, Immunovant, Aclaris, Morphic, and Ventyx.

Larry Tiffany describes how GenrAb is leveraging neurodegenerative stress and immunoogenetic models from UTSW for antibody discovery.

Marty Driscoll describes how OncoNano is utilizing a tumor's acidic environment to develop therapies and imaging agents.

Vinny Jindal describes Secretome's approach to using neonatal cardiac progenitor cells.

Dan Siegwart describes what goes into getting LNPs to places in the body beyond the liver, and how he has co-founded ReCode Therapeutics.

Claire Aldridge explains how Form Bio was derived from the work that Colossal Bio was doing in Texas.

Jeff Keyser tells us about trying to help patients recover from surgeries more efficiently and the phase 2 data that led to Renibus' BTD.

Dr. Olson describes work that has come out of his lab that aims to help diseases such as muscular dystrophy and hypertrophic cardiomyopathy.

David Greenberg describes Solenic Medical's non-pharmaceutical solution to implant infections.

Nicole Small describes the investments in infrastructure that are being made to grow entrepreneurs’ ability to keep science at home in DFW.

Elazer Edelman explains how MIT acts as a bridge between the development of technology and the introduction of technology.